secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2024-06-10T23:59:59+00:00
Accession:  0001213900-24-051263
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA and EMA back MoonLake's Phase 3 program for sonelokimab in psoriatic arthritis
--------------------------------------------------------------------------------

- FDA and EMA unanimously supported MoonLake's proposed Phase 3 IZAR program for sonelokimab in PsA.
- Phase 3 design: ~1,500 patients across two trials (IZAR-1 bio-naïve, IZAR-2 TNF-IR with risankizumab reference).
- Doses 60mg and 120mg; primary endpoint ACR50 at week 16; first patient Q4 2024, topline readout end-2026.
- Follows positive FDA/EMA feedback for HS Phase 3 VELA program; Phase 3 HS recruitment already started.
- Phase 2 ARGO data plus IZAR intended to support BLA and EU MAA for sonelokimab in PsA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000121390024051263/0001213900-24-051263-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000121390024051263/ea0207582-8k_moonlake.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-051263

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer